DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoraci...(s over existing technology. The impelle...),Health

Date:10/14/2009

s over existing technology. The impeller's magnetic levitation eliminates premature friction wear and allows a wide gap between blood contact surface areas, enabling blood to flow through the pump unimpeded in a smooth non-turbulent fashion. In addition, a hydrodynamic failsafe, that enables the pump to continue working under conditions that might cause other devices to fail, provides reassurance to patients and physicians.

"We are excited to bring DuraHeart to our customers during this important meeting," said Pinon. "As we expand our clinical experience worldwide and prepare to engage new centers in new markets, feedback from our customers will ensure we stay on track and offer the best treatment option."

The EACTS meeting offers Terumo Heart an excellent opportunity to showcase its unique technology and gather valuable feedback from cardiac surgeon customers in the field of Heart Failure surgery. To learn more about the DuraHeart LVAS program, please visit Terumo Heart representatives at exhibit booth number 32 during the meeting.

About Heart Failure
More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization. The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transplants annually, but less than 3,000 will receive a transplant each year. A large number of people who suffer from severe heart failure do not qualify for transplantation due to other health issues. An alternative for these patients is access to artificial mechanical assist devices. Left Ventricular Assist Systems are a type of mechanical circulatory device specifically designed to improve the quality of life of the patients waiting for donor hearts, as well as those
'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit
2. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
3. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
4. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
5. Improving survival rates among users of left ventricular assist devices
6. First Implant of DuraHeart(TM) Left Ventricular Assist System (LVAS) in Japanese Clinical Trial
7. Heart Failure Patients With Normal Left Ventricular Ejection Fraction Dont Benefit From Treatment With Angiotensin II Receptor Blocker
8. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
9. Hahnemann University Hospital Awarded Certification From the Joint Commission for Ventricular Assist Devices
10. Expert consensus on catheter ablation of ventricular arrhythmias
11. MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation